STEBA Biotech is a privately owned biotechnology company headquartered in Luxembourg with offices in France, Israel, Switzerland, and the US.  
Steba Biotech’s flagship product, TOOKAD®, for treatment of prostate cancer, is a first-in-class photosensitizer derived from palladium-substituted bacteriochlorophyll and developed in collaboration with the Weizmann Institute. It was designed to address limitations of previous attempts in photodynamic therapies. Through its high solubility and activation with low energy, near-infrared light, TOOKAD® enables highly localized vascular occlusion that triggers targeted necrosis of tumor lesions, while sparing surrounding healthy tissue.
Based on  positive results from Phase 3 clinical trials in Europe and Latin America  STEBA Biotech has received, marketing authorization for  TOOKAD®  from the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the Mexican health authority. TOOKAD® has also been submitted for marketing authorization to other Latin American countries, the European Union and Israel.
STEBA Biotech is also pursuing early stage studies Phase I/IIa of TOOKAD® in other solid tumors (esophageal cancer, urothelial carcinoma, advanced prostate cancer, renal carcinoma, and triple negative breast cancer) in collaboration with Memorial Sloan Kettering Cancer Center, the Weizmann Institute, and Oxford University.